New combo aims to control kidney cancer when standard meds fail
NCT ID NCT06222593
First seen Apr 06, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests whether adding bicalutamide to sunitinib can safely control advanced kidney cancer that has stopped responding to standard targeted therapy. About 28 adults with this type of cancer will receive the combination and be monitored for side effects and tumor shrinkage. The goal is to manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UB/ Great Lakes Cancer Care
RECRUITINGBuffalo, New York, 14203, United States
Conditions
Explore the condition pages connected to this study.